Related Experiment Video
Updated: Jan 17, 2026
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2 trial
Paola Leone1, Robert M Lober2,3, Jeremy Francis1
1Rowan-Virtua Health College of Medicine and Life Sciences, Rowan-Virtua SOM and Translational Biomedical Engineering and Sciences, Stratford, NJ, USA.
Abstract:
This open-label phase 1/2 clinical study uses a novel recombinant vector, rAAV-Olig001, with selective tropism for oligodendrocytes, to deliver gene therapy for Canavan disease (CD), a rare leukodystrophy characterized by defective aspartoacylase and elevated N-acetyl-aspartic acid (NAA) concentrations. A total of 8 participants received intracranial doses of 3.7 × 1013 vector genomes (vg) of rAAV-Olig001-ASPA (MYR-101), with an interim analysis at 12 months. The primary objective was to assess the safety of intracranial dosing of MYR-101 in children with typical CD. Efficacy measures included Mullen Scales of Early Learning (MSEL), Gross Motor Function Measure (GMFM) and analysis of NAA, myelination, white matter and extracellular water content in the brain. The participants were White; 5 (62.5%) were male. Of the participants, 7 (87.5%) experienced ≥1 serious adverse event, none of which were considered MYR-101 related. All participants experienced ≥1 adverse event. All adverse events and serious adverse events resolved fully. Treatment reduced NAA concentrations in cerebrospinal fluid (P = 0.0008), increased myelination (P = 0.0137) and improved MSEL developmental outcomes (P = 0.0171). Thus, interim results suggest that gene therapy with MYR-101 is well tolerated and shows early effects in CD. While these findings are preliminary, reductions in NAA concentrations indicate ASPA expression and increases in myelination and imply successful targeting of oligodendrocytes. These results may support the development of similar gene therapy strategies for other demyelinating and metabolic brain disorders. ClinicalTrials.gov registration: NCT04833907 .
Insights
Gene therapy using MYR-101 shows promise for Canavan disease, reducing harmful brain chemical levels and improving myelination and development in children. The treatment was well-tolerated, with all adverse events fully resolving.
Area of Science:
- Neurology
- Gene Therapy
- Pediatric Rare Diseases
Background:
- Canavan disease (CD) is a rare, fatal leukodystrophy caused by aspartoacylase deficiency.
- Elevated N-acetyl-aspartic acid (NAA) levels are a hallmark of CD, leading to severe neurological impairment.
- Current treatments for CD are limited, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of rAAV-Olig001-ASPA (MYR-101) gene therapy in children with Canavan disease.
- To assess the impact of MYR-101 on NAA concentrations, myelination, and neurodevelopmental outcomes.
- To investigate the tolerability of direct intracranial gene therapy delivery in pediatric patients.
Main Methods:
- An open-label, phase 1/2 clinical study involving 8 participants with Canavan disease.
- Intracranial administration of rAAV-Olig001-ASPA (MYR-101) at a dose of 3.7 × 10^13 vector genomes.
- Interim analysis at 12 months, assessing safety, NAA levels, myelination, white matter integrity, and neurodevelopmental scores (MSEL, GMFM).
Main Results:
- MYR-101 was well-tolerated, with all adverse events resolving fully; no treatment-related serious adverse events were reported.
- Significant reduction in cerebrospinal fluid NAA concentrations (P=.0008).
- Increased myelination (P=.0137) and improved MSEL developmental outcomes (P=.0171) were observed.
Conclusions:
- Interim results suggest MYR-101 gene therapy is safe and demonstrates early efficacy in Canavan disease.
- Observed reductions in NAA and increases in myelination indicate successful gene delivery and target engagement of oligodendrocytes.
- These findings support further development of MYR-101 and similar gene therapies for demyelinating and metabolic brain disorders.
